Go Back

Company or ticker...

COMPASS Pathways

COMPASS develops psilocybin-based mental health treatments, mainly for treatment-resistant depression.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

CMPS

1.8B

0.0

n/a

88.71%

Key Facts

M. Cap

PS

PE

YTD

1.8B

0.0

n/a

88.71%

10MA

20MA

50MA

200MA

$CMPS

The Fullstack Investor

by Lin

v1.3

Join Now

Join Now

The Fullstack Investor

by Lin

v1.3

Join Now

Join Now

Join Now

Join Now